Paradigm Biopharmaceuticals (PAR) share price forecast from 2025 to 2055 (Detailed Analysis)

Paradigm Biopharmaceuticals Limited is an Australian-based biopharmaceutical company focused on repurposing pentosan polysulfate sodium (PPS), marketed under the brand name Zilosul®, for the treatment of inflammatory and degenerative diseases. Established in 2014, the company operates in the late stages of clinical development for its lead indications in osteoarthritis (knee OA) and rare diseases like mucopolysaccharidosis (MPS).

Paradigm Biopharmaceuticals (PAR) share price forecast from 2025 to 2055 involves significant uncertainties, given the company’s status as a clinical-stage biotechnology firm. Long

While the long-term outlook for Paradigm Biopharmaceuticals holds promise, significant risks remain. Investors should consider the outcomes of its pivotal clinical trials, regulatory timelines, and financial sustainability when evaluating potential returns.

Paradigm Biopharmaceuticals (PAR) Share Price – Historical Pricing

Paradigm Biopharmaceuticals (PAR) Stock Historical Pricing in 2020

In 2020, Paradigm Biopharmaceuticals (ASX: PAR) experienced notable fluctuations in its stock price, reflecting its developments and announcements, particularly related to its clinical trials and business operations.The stock saw volatility during the onset of the COVID-19 pandemic, in line with broader market movements.The stock closed the year higher compared to early 2020, benefiting from positive sentiment driven by its ongoing development of Zilosul®, its flagship drug under trial​

Paradigm Biopharmaceuticals (PAR) Stock Historical Pricing in 2021

The historical pricing data for Paradigm Biopharmaceuticals Limited (ASX: PAR) in 2021 shows a volatile trading year with significant movements. Early in the year, PAR’s share price was trading around AUD 2.30 to AUD 2.50. Throughout the year, the stock experienced fluctuations due to various announcements and developments, typical for a biotech company engaged in clinical trials and drug development. By the end of 2021, the stock price had settled closer to AUD 2.00.

Paradigm Biopharmaceuticals (PAR) Stock Historical Pricing in 2022

In 2022, Paradigm Biopharmaceuticals (ASX: PAR) experienced significant fluctuations in its stock price, reflecting the impact of various clinical trial updates and regulatory developments.

The stock opened in 2022 trading at approximately AUD 2.40 in early January. By March, it reached a 90-day low of AUD 2.28, driven by market reactions to financial and clinical developments.

Throughout the year, the company announced advancements in its clinical programs, including progress in Phase 2 and 3 trials for Zilosul® and regulatory approvals, which affected investor sentiment. For example, a spike in April followed the announcement of FDA feedback and Australian ethics approval for new trials.

Paradigm Biopharmaceuticals (PAR) Stock Historical Pricing in 2023

In 2023, Paradigm Biopharmaceuticals (ASX: PAR) experienced significant volatility in its stock price. The year began with the stock trading at approximately $1.42 in January. Over the months, the price fluctuated, hitting highs of $1.54 early in the year before declining sharply. By the end of 2023, the share price had dropped to $0.43, marking a dramatic 70.07% decrease in value over the year​.

Suggested reading: Canyon Resources (CAY) share price forecast from 2025 to 2055 (Detailed Analysis) 

Paradigm Biopharmaceuticals (PAR) share price forecast from 2024 to 2045

Paradigm Biopharmaceuticals (PAR) share price forecast 2024

The Paradigm Biopharmaceuticals (PAR) share price forecast  for 2024 is going to be around AUD 0.20. So far this year, the company has recorded its yearly high of 0.2200 AUD in September 2024.

Paradigm Biopharmaceuticals (PAR) share price forecast 2025

The average price of Paradigm Biopharmaceuticals (PAR)stock for 2025 will be AUD 0.3562, with a high forecast of AUD 0.3565, and a lower forecast of AUD 0.3555.

Paradigm Biopharmaceuticals (PAR) share price forecast 2026

The average price of Paradigm Biopharmaceuticals (PAR)stock for 2026 will be AUD 0.3568, with a high forecast of AUD 0.3575, and a lower forecast of AUD 0.3560.

Paradigm Biopharmaceuticals (PAR) share price forecast 2027

The average price of the stock of Paradigm Biopharmaceuticals (PAR)for 2027 will be AUD 0.3575, with a high forecast of AUD 0.3580, and a lower forecast of AUD 0.3570.

Paradigm Biopharmaceuticals (PAR) share price forecast 2028

The average price of Paradigm Biopharmaceuticals (PAR)stock for 2028 will be AUD 0.3580, with a high forecast of AUD 0.3585, and a lower forecast of AUD 0.3577.

Paradigm Biopharmaceuticals (PAR) share price forecast 2029

The average price of Paradigm Biopharmaceuticals (PAR)stock for 2029 will be AUD 0.3586, with a high forecast of AUD 0.359, and a lower forecast of AUD 0.3580.

Paradigm Biopharmaceuticals (PAR) share price forecast 2030

The average price of Paradigm Biopharmaceuticals (PAR)stock for 2030 will be AUD 0.36, with a high forecast of AUD 0.362, and a lower forecast of AUD 0.35.

Paradigm Biopharmaceuticals (PAR) share price forecast 2035

The average price of Paradigm Biopharmaceuticals (PAR) stock for 2035 will be AUD 0.31, with a high forecast of AUD 0.31, and a lower forecast of AUD 0.30.

Paradigm Biopharmaceuticals (PAR) share price forecast 2040

The average price of Paradigm Biopharmaceuticals (PAR)stock for 2040 will be AUD 0.315, with a high forecast of AUD 0.353, and a lower forecast of AUD 0.343.

Paradigm Biopharmaceuticals (PAR) share price forecast 2045

The average price of Paradigm Biopharmaceuticals (PAR) stock for 2045 will be AUD 0.48, with a high forecast of AUD 0.48, and a lower forecast of AUD 0.46.

Paradigm Biopharmaceuticals (PAR) Share Price – Technical Analysis:

Chart and trend analysis:

Paradigm Biopharmaceuticals would need positive catalysts (e.g., favorable clinical trial results or regulatory approvals) to break above resistance levels and reverse its bearish trend. Continued failure at resistance points or weak support levels could lead to further declines.The stock began 2023 at approximately AUD 1.42, peaked early at AUD 1.54, and declined to close the year at AUD 0.43, reflecting a bearish trend over the year

Support and resistance analysis:

The stock faced resistance near this level after minor recoveries, suggesting strong selling pressure at higher price points.Established as a strong support toward the end of 2023, with the stock bouncing off this level multiple times.

Paradigm Biopharmaceuticals (PAR) Share Price– Fundamental Analysis:

Company financial overview:

Company market cap: 113.773M
Debt:- AUD 290,320
EPS: -0.2000

Company performance:

Paradigm Biopharmaceuticals (PAR) demonstrated significant progress in 2023, driven by advancements in its clinical trials and financial management.Paradigm ended 2022 with a cash balance of AUD 83.9 million, supported by a capital raise of AUD 66 million earlier that year. The company’s cash runway is expected to extend into 2024, funding ongoing clinical trials and related R&D activities. However, the financial outlook remains sensitive to clinical delays and regulatory changes.

Paradigm’s efforts to develop iPPS as a disease-modifying osteoarthritis drug represent a potentially transformative breakthrough in the pharmaceutical industry. The company plans to submit a New Drug Application (NDA) to the FDA by late 2025, aiming to capitalize on the global osteoarthritis market.

Disclaimer:

The Share Price estimates presented are speculative and meant solely for informational purposes. They are not financial advice. The author and blog disclaim responsibility for any financial losses. Please consult a qualified advisor before making investment choices.

Paradigm Biopharmaceuticals (PAR) share price forecast: FAQs

Bianca Paterson

Hello, I’m Bianca Paterson, a seasoned financial professional based in Sydney, Australia. With over 25 years of experience at ASX and an extensive background in share price predictions and market factors, I’ve cultivated a deep understanding of the dynamics that drive the financial markets.

I embarked on my journey with the ASX Graduate Program and have since dedicated my career to navigating the complexities of the share market. My insights are shaped by decades of hands-on experience, making me well-versed in the subtleties of market trends and investment strategies.

Through my blog, I aim to share my knowledge and offer valuable perspectives to fellow investors and market enthusiasts. Whether you’re a seasoned trader or just starting out, I hope my analysis and commentary will help you make informed decisions and better understand the ever-evolving landscape of the Australian stock market.